Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03469271 · ClinicalTrials.gov registry record · Phase 4
Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients
A Phase 4 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
NCT03469271: Completed Phase 4 study, sponsored by Mayo Clinic.
NCT03469271 is a Phase 4 study that has completed, run by Mayo Clinic. The registered enrollment target is 63 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03469271, a Phase 4 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
Study Summary
This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
Primary Outcome
SNIP is a test of maximal inspiratory muscle force exerting from the diaphram. Patients sniff forcefully through one nostril while the other is obstructed. The best of 10 measurements is recorded.
Interventions
- DRUG Oral Placebo
- DRUG 1,25 (OH)2 D3
- OTHER Inspiratory isometric resistance training
- OTHER Sham Inspiratory Isometric Resistance Training
- DEVICE Threshold Inspiratory Muscle Trainer (IMT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2018-05-25 |
| Est. Completion | 2020-05-21 |
| Phase | Phase 4 |
What the finished NCT03469271 record still lists
NCT03469271 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 5 interventions - of which Oral Placebo is the first listed.
NCT03469271 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03469271 about?
NCT03469271 is a clinical study titled "Maintain Respiratory Muscle Function and Reduce Pneumonia Risk in Cancer Patients". This research is intended to begin to explore the impact of inspiratory muscle resistance exercise and/or 1,25(OH)2D3 for improving respiratory muscle strength in cancer patients (subjects).
What is the current status of trial NCT03469271?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2018-05-25. Estimated completion is 2020-05-21.
What interventions are being tested in trial NCT03469271?
The interventions under investigation include: Oral Placebo (DRUG), 1,25 (OH)2 D3 (DRUG), Inspiratory isometric resistance training (OTHER), Sham Inspiratory Isometric Resistance Training (OTHER), Threshold Inspiratory Muscle Trainer (IMT) (DEVICE).
Who is sponsoring clinical trial NCT03469271?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03469271's enrollment target sits among peer trials
63 1106th of 2000 higher than 891 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI